Syros Pharmaceuticals Inc (SYRS)

A. Company Overview

Syros Pharmaceuticals Inc. is a biopharmaceutical company focused on advancing innovative therapies for hematologic malignancies, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The company's mission is to develop new standards of care aimed at addressing significant unmet needs in the treatment of patients suffering from these blood disorders. Syros is particularly driven by the aspiration to assist patients who have not responded to conventional targeted therapies.

The company is advancing its lead product candidate, tamibarotene, a selective retinoic acid receptor alpha (RARα) agonist. This small molecule drug is under investigation through various clinical trials, including SELECT-MDS-1 and SELECT-AML-1, targeting distinct patient subsets defined by the overexpression of the RARα gene.

B. Product Pipeline

Tamibarotene

Tamibarotene is a novel oral agent designed to selectively activate RARα. By binding to RARα receptors that are often overexpressed in certain blood malignancies, tamibarotene promotes myeloid differentiation, inhibits cell proliferation, and facilitates the clearance of immature blood cells, known as blasts.

Clinical Trials

• SELECT-MDS-1: This Phase 3 clinical trial investigates the efficacy of tamibarotene in combination with azacitidine for newly diagnosed patients with higher-risk myelodysplastic syndrome (HR-MDS) positive for RARα overexpression. The trial aims to demonstrate superior complete response (CR) rates compared to a control arm receiving azacitidine alone. The trial protocol was amended in March 2023 to increase the total patient enrollment to approximately 550 to also evaluate overall survival as a critical secondary endpoint. The FDA has granted Fast Track Designation for this study, highlighting its potential to provide significant therapeutic benefits.
• SELECT-AML-1: In this randomized Phase 2 clinical trial, tamibarotene is examined in combination with venetoclax and azacitidine, focusing on patients newly diagnosed with unfit AML who exhibit RARα overexpression. Initial data presented at the December 2023 American Society of Hematology meeting indicated a CR/CRi rate of 100% among patients treated with the triplet therapy compared to 70% in the control group. The trial also assesses safety and overall efficacy, reinforcing the strategy to address a population with substantial unmet medical needs.

Market Potential

The market opportunity for tamibarotene is considerable, with estimates suggesting that approximately 50% of HR-MDS patients and about 30% of AML patients exhibit RARα overexpression. In the United States and Europe, about 18,500 HR-MDS patients and 25,000 unfit AML patients are diagnosed annually, making the potential global market for these conditions substantial, with projections suggesting growth to approximately $4.7 billion and $7.5 billion, respectively, by 2028.

C. Other Assets

SY-2101

SY-2101 was previously developed as an oral treatment for acute promyelocytic leukemia (APL), a specific subtype of AML. Although the agent exhibited bioavailability and a tolerable safety profile in earlier clinical trials, development was halted in favor of prioritizing ongoing work with tamibarotene.

SY-5609

SY-5609, a selective CDK7 inhibitor, is being evaluated for further licensing opportunities. Preliminary data from a Phase 1/1b clinical trial indicated encouraging activity in solid tumors, although no ongoing development has been confirmed as priorities shift towards tamibarotene.

D. Intellectual Property

Syros Pharmaceuticals maintains a robust intellectual property portfolio, which includes multiple patents concerning tamibarotene and its applications, particularly focusing on methods of treatment based on biomarkers like RARA. As of December 31, 2023, the company holds 25 issued U.S. patents and 131 corresponding applications globally.

E. Collaborations and Partnerships

The company has formed strategic partnerships to enhance its capabilities. Notably, Syros has worked with Qiagen to develop a companion diagnostic test to identify RARα overexpression in patients. This collaboration aligns with the company's clinical strategies and strengthens its positioning in precision medicine for blood disorders.

The licensing agreement with TMRC Co. Ltd. encompasses the commercial development of tamibarotene in several territories. These partnerships are essential for navigating the complex landscape of drug development and commercialization, particularly in the hematologic oncology space.

F. Market Competition

Syros operates in a highly competitive environment characterized by established pharmaceutical companies and emerging biotech firms. The competition includes a variety of therapies currently available and those in clinical development for AML and MDS. Tamibarotene is being positioned uniquely through its targeted action on RARα, with no direct competitors identified in the same clinical category as a selective RARα agonist for these conditions.

G. Regulatory Environment

Navigating the regulatory landscape is crucial for Syros, which faces the stringent oversight associated with drug development, especially for oncology treatments. This entails extensive preclinical and clinical testing, compliance with strict guidelines from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and ongoing post-marketing surveillance upon approval.